ZA200402630B - Antibodies to non-functional p2x7 receptor diagnosis and treatment of cancers and other conditions - Google Patents

Antibodies to non-functional p2x7 receptor diagnosis and treatment of cancers and other conditions

Info

Publication number
ZA200402630B
ZA200402630B ZA2004/02630A ZA200402630A ZA200402630B ZA 200402630 B ZA200402630 B ZA 200402630B ZA 2004/02630 A ZA2004/02630 A ZA 2004/02630A ZA 200402630 A ZA200402630 A ZA 200402630A ZA 200402630 B ZA200402630 B ZA 200402630B
Authority
ZA
South Africa
Prior art keywords
cancers
antibodies
diagnosis
receptor
functional
Prior art date
Application number
ZA2004/02630A
Other languages
English (en)
Inventor
Alexander Barden Julian
Gidley-Baird Angus
Original Assignee
Intreat Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AUPR7430A external-priority patent/AUPR743001A0/en
Priority claimed from AUPR7431A external-priority patent/AUPR743101A0/en
Priority claimed from PCT/AU2002/000061 external-priority patent/WO2002057306A1/en
Application filed by Intreat Pty Ltd filed Critical Intreat Pty Ltd
Publication of ZA200402630B publication Critical patent/ZA200402630B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
ZA2004/02630A 2001-09-03 2004-04-02 Antibodies to non-functional p2x7 receptor diagnosis and treatment of cancers and other conditions ZA200402630B (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
AUPR7430A AUPR743001A0 (en) 2001-09-03 2001-09-03 Diagnosis and treatment of irritable bowel syndrome
AUPR7431A AUPR743101A0 (en) 2001-09-03 2001-09-03 A cancer therapeutic
PCT/AU2002/000061 WO2002057306A1 (en) 2001-01-17 2002-01-17 Antibodies to non-functional p2x7 receptor diagnosis and treatment of cancers and other conditions
PCT/AU2002/001204 WO2003020762A1 (en) 2001-09-03 2002-09-03 Antibodies to non-functional p2x7receptor, diagnosis and treatment of cancers and other conditions

Publications (1)

Publication Number Publication Date
ZA200402630B true ZA200402630B (en) 2005-06-29

Family

ID=41706691

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2004/02630A ZA200402630B (en) 2001-09-03 2004-04-02 Antibodies to non-functional p2x7 receptor diagnosis and treatment of cancers and other conditions

Country Status (9)

Country Link
JP (1) JP4467973B2 (https=)
CN (2) CN100497386C (https=)
AU (1) AU2002322192B2 (https=)
CA (1) CA2459348C (https=)
MY (1) MY142283A (https=)
NZ (2) NZ549019A (https=)
TW (1) TWI329648B (https=)
WO (1) WO2003020762A1 (https=)
ZA (1) ZA200402630B (https=)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4384852B2 (ja) 2001-01-17 2009-12-16 イントリート ピーティーワイ リミテッド 非機能性ｐ２ｘ７レセプター抗体、癌及びその他の容態の診断及び処置
WO2004053426A1 (en) * 2002-12-05 2004-06-24 Kla-Tencor Technologies Corporation Apparatus and methods for detecting overlay errors using scatterometry
US7344860B2 (en) 2003-04-03 2008-03-18 Bristol-Myers Squibb Company Polynucleotide encoding a novel human P2X7 splice variant, HBMYP2X7v
US8124730B1 (en) 2004-04-02 2012-02-28 Bristol-Myers Squibb Company Polynucleotide encoding a novel human P2X7 splice variant, HBMYP2X7v
US7767789B2 (en) * 2005-06-02 2010-08-03 University Hopitals of Cleveland Truncated proteins as cancer markers
JP2010505426A (ja) * 2006-10-10 2010-02-25 バイオスセプター インターナショナル リミテッド 非機能性ｐ２ｘ７受容体に対する抗体を産生するハイブリドーマ
WO2008043146A1 (en) * 2006-10-10 2008-04-17 Biosceptre International Limited Antibodies against non functional p2x7 receptor
ATE542139T1 (de) * 2007-09-14 2012-02-15 Biosceptre Int Ltd Purinerge (p2x)-rezeptoren in extrazellulärer körperflüssigkeit
AU2013238152B2 (en) * 2007-09-14 2015-09-24 Biosceptre International Limited Purinergic (P2X) receptors in extra-cellular body fluid
ES2619681T3 (es) 2007-09-14 2017-06-26 Biosceptre (Aust) Pty Ltd Novedosos epítopos P2X7
CN102143978B (zh) 2008-07-04 2015-02-18 生物权威国际有限公司 抗p2x7肽和表位
CN101469352B (zh) * 2008-08-29 2011-12-21 苏州福英基因科技有限公司 一种早期子宫癌原位杂交检测试剂盒
EP2467404B1 (en) 2009-08-20 2015-09-30 Biosceptre International Limited Anti p2x7 receptor antibodies and fragments thereof
WO2011075789A1 (en) 2009-12-24 2011-06-30 Biosceptre International Limited Antibodies to non-functional oligomeric p2x7 receptors
EP2613808B1 (en) 2010-09-10 2017-11-08 Biosceptre (Aust) Pty Ltd Companion animal cancer treatments with an anti p2x7 antibody
MX349321B (es) * 2011-07-01 2017-07-21 Biosceptre (Aust) Pty Ltd Terapia combinada.
EP2990800A1 (en) * 2014-08-29 2016-03-02 Fundació Institut d'Investigació en Ciències de la Salut Germans Trias i Pujol Neprilysin as heartfailure (HF) prognostic marker
US12121539B2 (en) 2015-09-11 2024-10-22 Biosceptre (Aust) Pty Ltd Chimeric antigen receptors and uses thereof
MX2019004410A (es) * 2016-10-21 2019-09-26 Biosceptre Uk Ltd Particulas citotoxicas.
CN112166193A (zh) 2018-05-21 2021-01-01 生物权威（英国）有限公司 具有经修饰的接头结构域的嵌合抗原受体及其用途
CN110054691B (zh) * 2019-05-09 2021-09-07 潍坊医学院 一种抗人p2rx7单克隆抗体的杂交瘤细胞系
CN114173811A (zh) * 2019-07-26 2022-03-11 生物权威(澳大利亚)有限责任公司 P2x7受体靶向治疗
BR112023020659A2 (pt) * 2021-04-08 2023-12-05 Biosceptre Aust Pty Ltd Métodos para controlar a atividade de célula imune

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6133434A (en) * 1997-04-28 2000-10-17 Glaxo Group Limited Purinergic receptor
JP4384852B2 (ja) * 2001-01-17 2009-12-16 イントリート ピーティーワイ リミテッド 非機能性ｐ２ｘ７レセプター抗体、癌及びその他の容態の診断及び処置

Also Published As

Publication number Publication date
AU2002322192B2 (en) 2008-05-01
WO2003020762A1 (en) 2003-03-13
CN100497386C (zh) 2009-06-10
CN101445555B (zh) 2013-07-03
CN101445555A (zh) 2009-06-03
NZ565994A (en) 2010-02-26
JP2005513416A (ja) 2005-05-12
CA2459348A1 (en) 2003-03-13
JP4467973B2 (ja) 2010-05-26
CA2459348C (en) 2013-06-18
TWI329648B (en) 2010-09-01
CN1625565A (zh) 2005-06-08
MY142283A (en) 2010-11-15
NZ549019A (en) 2008-05-30

Similar Documents

Publication Publication Date Title
ZA200402630B (en) Antibodies to non-functional p2x7 receptor diagnosis and treatment of cancers and other conditions
IL157142A0 (en) Modified antibodies and methods of use
IL174896A0 (en) Correlation between the fucose conteny/galactose content ratio of anti-rhesus-d and anti-hla-dr antibodies and the adcc activity
AU2003223285A8 (en) Human monoclonal antibodies to influenza m2 protein and methods of making and using same
IL206980A0 (en) Antibodies that bind human interleukin-18 and methods of making and using
AU2003295411A8 (en) Human monoclonal antibodies to heparanase
IL158316A0 (en) Therapeutic and diagnostic uses of antibody specificity profiles
HUP0600688A3 (en) Methods of administering anti-tnf alpha antibodies
IL168058A0 (en) Antibodies that bind celi-associated ca 125/0722p and methods of use thereof
ZA200501308B (en) Agonism of the 5HT2a receptor for treatment of thermoregulatory dysfunction
EP1355563A4 (en) METHODS OF PREVENTING AND TREATING CANCER WITH ANTI-C3B (I) ANTIBODIES
IL200604A0 (en) Human monoclonal antibodies against cd30
HUP0301002A3 (en) Dual specificity antibodies and methods of making and using
AU2003256078A8 (en) Method of diagnosing colon and gastric cancers
WO2004069873A3 (en) Antigen/antibody or ligand/receptor glycosylated specificity exchangers
AU2002348297A8 (en) Proteonomic methods for diagnosis and monitoring of breast cancer
EP1474176A4 (en) HUMAN G PROTEIN-COUPLED RECEPTOR, HGPRBMY31, VARIANTS AND METHODS OF USING THE SAME
AU2003218208A8 (en) Methods for diagnosis and prognosis of cancer
GB0200260D0 (en) Microparticles and methods of making them
AU2002224664A1 (en) Antibodies to non-functional p2x7 receptor diagnosis and treatment of cancers and other conditions
EP1163365A4 (en) DIAGNOSIS AND THERAPY OF EARLY OVARY FAILURE
EP1506002A4 (en) TREATMENT OF CROHN'S DISEASE OR PSORIASIS FROM ANTI-INTERFERON GAMMA ANTIBODIES
HUP0402540A3 (en) Pharmaceutical combinations of adenosine a-2a and betha-2-adrenergic receptor agonists
PT1448566E (pt) Antagonistas do receptor quimioquina e metodos de utilizacao do mesmo
EP1461351A4 (en) METHOD AND REAGENT FOR DIABETES DIAGNOSIS AND TREATMENT